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Introduction
Aberrant activation of the phosphoinositide 3-kinase (PI3K) signaling pathway has been widely implicated in the pathogenesis of many cancers (1) . Constitutive activation of this pathway leads to unregulated proliferation, evasion of apoptosis, and altered metabolism via the Warburg effect (2, 3) . PI3K-dependent activity is frequently elevated due to amplification (4) or gain-of-function mutations of the PIK3CA gene (5) , as well as loss of function of the phosphatase and tensin homolog (PTEN) tumor suppressor gene, a critical negative regulator of the pathway (6) . In addition, increased pathway activity has been associated with resistance to anticancer therapies (7, 8) .
The significance of PI3K signaling for tumor survival and proliferation has prompted investigation of this pathway as an anticancer drug target (2) , leading to the development of candidate therapeutics designed to inhibit the activity of pathway components such as PI3K, mammalian target of rapamycin (mTOR), and AKT.
GDC-0941 is a highly specific class 1 PI3K inhibitor with a favorable tolerability and pharmacokinetic profile (9) , which is currently in clinical development. GDC-0941 effectively inhibits all four class 1 isoforms of PI3K (p110α, β, δ, and γ) (9, 10), which have been implicated in the development of human solid tumors (p110α and β) and lymphoid malignancies (p110δ and γ) (9, 10) . Early clinical data indicate that GDC-0941 achieves pharmacodynamic inhibition of the PI3K pathway at exposures that induce efficacy in preclinical models (11) (12) (13) (14) , and provide evidence of antitumor activity. GDC-0980, which is also in early-phase clinical development, is a potent inhibitor of both the mTOR kinase (both TORC1 and TORC2 complexes) and the class 1 PI3K (all four isoforms). By inhibiting the PI3K signaling pathway at multiple Draft: 7 points, it is anticipated that greater suppression of the pathway can be achieved than through inhibition of any one target alone, although there is a risk of increased ontarget toxicity and a correspondingly less favorable therapeutic index. In preclinical studies, GDC-0980 showed effective PI3K-mTOR pathway inhibition and broad antitumor activity (15) .
Preclinical data support PTEN loss and PIK3CA mutations as predictive markers for response to GDC-0941 and GDC-0980 treatment in breast cancer and other tumor types (13, 15, 16) . Although clinical studies are specifically evaluating these and other biomarkers to further characterize those patients who will benefit most from these targeted therapies, additional characterization of predictive biomarkers in non-small-cell lung cancer (NSCLC) is required to inform clinical trial biomarker strategies in this indication. PIK3CA itself is infrequently mutated in this tumor type, particularly in non-squamous NSCLC (1) . Thus biomarkers in NSCLC may differ from those analyzed in other indications, as the mode of PI3K pathway activation may be distinct.
NSCLCs comprise a highly heterogeneous group of diseases including multiple histologic subtypes. The most common forms of NSCLC in the USA and Europe are adenocarcinoma (50%) and squamous cell carcinoma (30%) with a variety of less common subtypes accounting for the remainder. Until recently, histologic subtype was not a factor in chemotherapy treatment decision-making. However, histology is becoming an increasingly important factor both in terms of safety and efficacy. For example, bevacizumab (Avastin; Genentech, South San Francisco, CA) is contraindicated in patients with squamous cell carcinomas of the lung due to an increased risk of hemoptysis (17) . Pemetrexed (Alimta; Eli Lilly, Indianapolis, IN) is also not prescribed for patients with the squamous subtype due Draft: 7 to lack of efficacy, which may be related to higher expression of the drug target thymidylate synthase in squamous tumors making effective target blockade challenging (18) . As a result, the standard of care regimens for front-line therapy are different for squamous and non-squamous NSCLC. Thus for the foreseeable future, it will be necessary to establish distinct clinical development plans for new molecular entities for these two subtypes of NSCLC.
Here, we present a detailed study of alterations relevant to PI3K and mTOR signaling in a collection of NSCLC tumor samples to assess the prevalence and overlap of these alterations and their relationship to histologic subtypes. The genes studied include core pathway components such as PIK3CA and PTEN, as well as FBXW7, which encodes a ubiquitin ligase that degrades mTOR (19) , and GOLPH3, which is amplified in NSCLC and associated with mTOR inhibitor sensitivity (20) . A detailed understanding of PI3K pathway alterations in NSCLC will enable a more precise delineation of candidate target populations within histologic subtypes, facilitating clinical trial design and validation of predictive biomarkers.
Materials and Methods
Tumor samples and cell lines
A panel of NSCLC tumor samples was selected for this study from the Genentech tumor bank. Squamous or adenocarcinoma histology was confirmed by pathologic examination. This panel consisted of a total of 172 frozen and 112 formalin-fixed paraffinembedded (FFPE) lung tumor samples with a tumor content of at least 50%. It was not possible to run all assays on all samples, either due to samples being exhausted by one
Research. at early passage in the Genentech cell bank and authenticated using a muliplex STR assay. All cell lines were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, non-essential amino acids, and 2 mmol/L L-glutamine.
Expression analysis in tumor tissue
Gene expression analysis was carried out on RNA extracted from FFPE NSCLC tumor samples using the High Pure FFPE RNA Micro Kit (Roche, Nutley, NJ) after deparaffinization with Envirene (xylene substitute), as described by Walter et al. (21) . The 96-gene quantitative reverse-transcription polymerase chain reaction (qRT-PCR) assay consisted of epithelial-mesenchymal markers, Human Epidermal Growth Factor Receptor (HER) family signaling factors, PI3K pathway signaling components, and two reference genes, and has been described previously (21) . Cycle threshold (Ct) values were converted to relative expression as follows: relative expression = 2 -ΔCt where ΔCt is the mean of the target gene minus the mean of the reference genes. Hierarchical clustering of differentially expressed genes was carried out on median-centered data with the complete linkage method using Cluster v3.0 (22) and subsequently visualized using Treeview (23). RNA from frozen NSCLC tumors was run on the Human Genome U133
Research. Plus 2.0 Array (Affymetrix, Santa Clara, CA) as previously described (24). PIK3CA expression was evaluated with probe set 204369_at, and compared with array CGH data (described below) from the same samples.
Expression analysis in cell lines
To identify genes that showed expression changes upon PI3K inhibition, cell lines H1975, H2170, H226, H441, LFXL529, and SW1573 were plated in T25 flasks in duplicate and treated with 1 µM GDC-0941, 1 µM GDC-0980, or dimethyl sulfoxide (DMSO) (vehicle control) for 6 hours. RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA). cDNA was synthesized using the High Capacity cDNA Reverse 
Mutation analysis
Mutation analyses were carried out on genomic DNA extracted from FFPE tumors using the QIAamp FFPE kit (Qiagen) after deparaffinization with Envirene, as well as genomic DNA extracted from cell lines using the QIAamp kit (Qiagen). Mutations in PIK3CA, KRAS, BRAF, and NRAS were detected using qPCR as described in the Supplementary Materials and Methods.
Copy number and comparative genomic hybridization (CGH) array analysis
Array CGH studies were performed as previously described (25) (28) . This assessed both frequency and magnitude of copy number variations for the chromosome region encompassing a gene of interest, and determined a significance threshold for any observed aberration. This enabled the statistical significance of copy number variation to be evaluated. NSCLC frozen tumor samples with both PIK3CA copy number data (array CGH) and mRNA expression data (Affymetrix array) were plotted together to confirm their correlation.
Copy number data has been deposited in the GEO database under accession numbers GSE20393 and GSE39793.
Frozen tumor and cell line DNA was subjected to copy number analysis using TaqMan Copy Number Assays (Applied Biosystems) according to the manufacturer's protocol, and described in more detail in the Supplementary Materials and Methods.
Fluorescence in-situ hybridization (FISH) analysis
FISH analysis was performed on cell line and FFPE tumor samples as described previously (29, 30) 
PTEN immunohistochemistry (IHC)
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Western blot analysis
Baseline and dose-response western blots were performed as described previously (16) . For PI3K inhibitor dose-response blots, cells were plated in 6-well plates and exposed 24 hours later to either GDC-0941 or GDC-0980 for 6 hours. Primary antibodies were used as previously described (16) .
Inhibitors and cell viability experiments
The PI3K inhibitors GDC-0941 (pan-PI3K) and GDC-0980 (dual PI3K/mTOR), and a MEK1/2 inhibitor used in this study were synthesized and provided by the Genentech Medicinal Chemistry group (9, 32, 33) . Cell viability was assessed with the Cell Titer Glo ATP luminescence assay (Promega, Madison, WI) using published protocols (16, 31) . Cells were exposed to inhibitors for a total of 72 hours and cell viability was measured at the time of dosing and after 72 hours, to determine whether the inhibitory effect was due to growth inhibition or cell death. No growth (0%) on the doseresponse curves represents the number of cells present before exposure to the inhibitors, and therefore viability values below that point are indicative of a cytotoxic effect. In vitro combination studies were performed as described previously (25) .
In vivo xenografts
NSCLC lines A549, H460, H520, HCC827, and H1975 were evaluated for in vivo efficacy as xenografts grown in immunocompromised mice. All lines were implanted in 6 to 8 week-old female athymic nude mice from Harlan Laboratories (Indianapolis, IN). 
Results
PI3K pathway alterations in NSCLC tumor samples
To assess biomarker prevalence across NSCLC histologic subtypes, we performed gene expression analysis on RNA from a set of 51 FFPE NSCLC tumor samples using Fluidigm Dynamic Arrays. Details of the gene expression assay are described in a separate manuscript (21) . Tumors were defined as squamous cell carcinomas or adenocarcinomas by pathologic examination (Fig. 1 , Supplementary (21, 34, 35) . Cluster 2 showed high expression of markers associated with a squamous cell carcinoma histology such as TP63 (36) and KRT6A, as well as markers of a mesenchymal-like phenotype such as TWIST1 and SNAI2 (Fig. 1) . The majority of EGFR and KRAS mutations occurred in the epithelial-like adenocarcinomas, consistent with previous reports that these alterations are associated with adenocarcinoma (37) . Several of the samples that were histologically squamous and harbored KRAS mutations clustered with the adenocarcinomas, which may reflect challenges inherent in pathologically distinguishing poorly differentiated adeno-squamous cancers; this is consistent with other reports that comprehensive profiling with multiple histology markers may be a more sensitive means of determining histologic subtype (38). Only two PIK3CA mutations were detected, and both were present in squamous cell carcinomas. As expected, mutations in NRAS and BRAF were not detected as they are rare in NSCLC.
To examine copy number alterations relevant to PI3K signaling, a panel of 79 frozen NSCLC tumor samples was analyzed by array CGH to determine genomic gains and losses for a series of candidate predictive biomarkers relevant to PI3K/mTOR pathway inhibitors. Of the tumor samples studied, 52 exhibited squamous histology and 27 had adenocarcinoma histology. Consistent with previous findings (39), we observed recurrent genomic alterations, including gains at 5p, 6p, 12p, and 14q and losses at 5q, 9p, and 10q ( Supplementary Fig. S1 ). Supervised analysis of copy number alterations showed a high frequency of PI3K/mTOR
Research. pathway alterations, with distinct patterns between histologic subtypes ( Fig. 2A) .
Specifically, loss of LKB1 and gain of EGFR were associated with adenocarcinoma samples, whereas AKT2 and PIK3CA gains and PTEN loss were associated with squamous histology.
To evaluate gene amplification across the chromosome 3 region encompassing the PIK3CA locus, GISTIC analysis (28) was conducted using data from the frozen NSCLC tumor samples. This analysis confirmed focal copy number gains at the PIK3CA locus in squamous tumors, but not in adenocarcinomas ( Supplementary Fig. S2A ). PIK3CA copy number in NSCLC tumors correlated with gene expression determined by microarray analysis (R = 0.90, Supplementary Fig.   S2B ). CGH plots from individual squamous NCSLC tumors demonstrated that the amplicon is centered at the PIK3CA locus ( Supplementary Fig. S3A ). Copy number analysis of PIK3CA was also carried out by qPCR on an independent set of 93 frozen tumor samples and showed a similar pattern of increased copy number in squamous tumors (Supplementary Fig. S3B ). Further investigation of PIK3CA copy number gains was carried out by fluorescence in situ hybridization (FISH) analysis.
The assay was validated initially in the Calu3 squamous NSCLC cell line because this cell line is known from CGH array data to have increased PIK3CA copy number (Sanger COSMIC database). Amplification of PIK3CA relative to the centromeric probe CEP3 was observed in Calu3 cells (Supplementary Fig. S4) . The assay was then applied to 41 adenocarcinoma and 43 squamous FFPE tumor samples; chromosomal amplification, defined by a PIK3CA/CEP3 ratio greater than or equal to 2.0, was observed in 37% of squamous but only 5% of adenocarcinoma samples, suggesting a significant association with squamous histology (P < 0.002, Fig. 2B, C) .
In 12 cases, matched primary and metastatic tumor samples were analyzed for
PIK3CA copy number using the FISH assay (Fig. 2D) . Amplification status differed between primary and metastatic samples in five of the cases: two patient samples were amplified (PIK3CA/CEP3 ratio >2.0) in the metastatic but not primary sample, whereas three were amplified in the primary but not the metastatic sample.
We also determined PTEN protein levels in 56 adenocarcinoma and 43 squamous cell NSCLC tumor samples by immunohistochemistry (IHC), with intermediate levels of loss recorded as an H-score. Representative IHC staining is shown in Figure 3A 
PI3K pathway alterations in NSCLC cell lines
We aimed to determine whether similar pathway alterations were present in a panel of 29 NSCLC cell lines, and to use these cell lines to functionally validate the importance of PI3K pathway alterations in predicting sensitivity to selective inhibitors.
Baseline protein levels of selected pathway components were determined by western blotting (Supplementary Fig. S5 ). Cell lines were also characterized for KRAS, NRAS, BRAF, PIK3CA, and EGFR mutational status, as well as copy number alterations in EGFR, HER2, MET, MYC, AKT2, and PIK3CA (Supplementary Table   S2 ). Cell lines were classified into epithelial and mesenchymal subtypes based on published data (21) . Sensitivity to GDC-0941 was assessed in different genetic
backgrounds defined by the molecular analyses. We observed generally greater sensitivity to the selective PI3K inhibitor GDC-0941 in epithelial compared with mesenchymal cell lines (P < 0.04, Fig. 4A) ; four of the six least sensitive epithelial cell lines harbored RAS mutations, while the two most sensitive mesenchymal lines harbored PIK3CA mutations (Fig. 4A, B) . In addition, cell lines with receptor tyrosine kinase (RTK), PIK3CA alterations, or PTEN loss were significantly more sensitive to GDC-0941 as a class compared to those with RAS/RAF, LKB1, or no detected pathway alterations (P < 0.0001, Mann-Whitney test, Figure 4B) . Many of the cell lines with PI3K pathway activating events had more than one alteration in the pathway. One cell line, H1770, which showed evidence of PTEN loss but no other pathway alteration, was less sensitive than the models with at least two activating events. Expression of other candidate biomarkers such as FBXW7 and Golph3 was not associated with sensitivity to PI3K or dual PI3K/mTOR inhibition in this cell line
panel (data not shown). Comparison of half maximal inhibitory concentration (IC 50 )
values from these experiments (Fig. 4B, bottom) showed that the PI3K/mTOR inhibitor GDC-0980 had the broadest activity across the panel, although it was also most potent in cell lines with PI3K and RTK alterations (P < 0.002, Mann-Whitney test). In contrast to GDC-0941, GDC-0980 was active in cell lines with LKB1 loss. An allosteric MEK inhibitor had minimal activity in PI3K-activated models and was more potent in cell lines with RAF and RAS alterations than in cell lines without these alterations (P < 0.03, Mann-Whitney test), consistent with previous reports (40).
High-level MYC amplification was present in several cell lines, including the sensitive cell lines H1975 and H2170 (Supplementary Table S2 ), but was not associated with resistance to GDC-0941 or GDC-0980. Fig. 4D . Three of the models were also treated with GDC-0980 daily and orally at maximum tolerated doses of 2.5 or 5 mg/kg (Fig. 4D) . Treatment of NSCLC models with a KRAS mutation (A549) or concomitant KRAS and PIK3CA mutations (H460) with GDC-0941 resulted in 33% or 20% TGI, respectively (Fig. 4D ). GDC-0980 had greater antitumor activity in these models, with 62% TGI in A549 xenografts and 43% in H460 xenografts. By contrast, GDC-0941 and GDC-0980 showed comparable antitumor activity (67% and 68% TGI, respectively) in H520 tumors, which harbor both PIK3CA amplification and PTEN loss (Fig. 4D) . Additionally in two RTK-driven models (HCC827 and H1975), GDC-0941 showed greater than 100% TGI, indicative of tumor regression (Fig. 4D) .
Effects of GDC-0941 and GDC-0980 on signaling and feedback loops
We sought to determine whether sensitive and resistant cell lines showed distinct differences in pharmacodynamic effects on pathway signaling and pathwayregulated feedback loops, as such differences could have relevance to the clinical development of these inhibitors. The pharmacodynamic effects of the PI3K inhibitor GDC-0941 and the PI3K/mTOR inhibitor GDC-0980 were investigated by looking for changes in downstream components of the PI3K signaling pathway, in both sensitive (H1975) and resistant (H441) cell lines (Fig. 5A) . In H1975 cells, GDC-0941 and GDC-0980 treatment resulted in increased levels of cleaved poly-ADP ribose polymerase (PARP) and decreased levels of MCL-1 (both of which are hallmarks of apoptosis induction), consistent with the cytotoxic effect seen in the cell viability assays (Fig. 5A) . The reduction in levels of Cyclin D1 was indicative of cell cycle arrest. Phospho-4EBP1 was decreased more dramatically with GDC-0980, which is consistent with 4EBP1 being directly downstream of mTOR. The effects on Cyclin D1, pAKT, and p4EBP1 were more modest in the resistant H441 cell line.
The effect of PI3K/mTOR inhibition on transcriptional output of the pathway was also assayed in a subset of NSCLC cell lines in order to assess whether there were pharmacodynamic differences in transcriptional readouts in sensitive compared with resistant cell lines. In this analysis, we focused on transcripts that have been previously identified as readouts of PI3K inhibition in breast cancer models (16) (Fig.   5B ). Treatment of sensitive cell lines with the PI3K inhibitors resulted in increased levels of mRNA for some RTKs and signaling pathway genes, including ERBB3, MET, and PIK3IP1. In addition, transcript levels of AA1370, CCNG2, and YPEL2
were also increased by treatment with GDC-0941 and GDC-0980, consistent with the previously described role of these genes as part of a negative feedback loop that is regulated by PI3K signaling (16) . By contrast, the transcriptional effects of drug treatment on resistant cell lines were minimal. We also sought to determine whether predictive biomarker status would affect sensitivity to these combinations of agents by conducting in vitro combination screening. Combination effects were assessed in cell viability assays conducted across a range of concentrations of each compound. This approach allows visualization of percent inhibition at each combination of concentrations, as well as calculation of measures of synergy using the Bliss independence model, with positive Bliss scores indicating greater than additive effects (25) . We found that the combination of GDC-0941 with paclitaxel was additive or modestly greater than additive, and that this effect was independent of candidate biomarkers (Fig. 6A) . The GDC-0941/erlotinib combination showed slightly higher Bliss scores, with a trend toward greater combination effects in cell lines with RTK activation (Fig. 6B) . Finally, the GDC-0941/MEK inhibitor combination showed the strongest combination effects, and was particularly effective in cell lines with EGFR activation, PIK3CA mutations, or KRAS mutations (Fig. 6C) .
Discussion
Lung cancer is a disease characterized by a high degree of molecular complexity. Whole-genome sequencing of a single NSCLC tumor sample revealed more than 50,000 high-confidence single-nucleotide variants in one cancer specimen (42) . An important challenge is dissecting this complexity, and determining the association between alterations in specific signaling pathways and sensitivity to It has previously been suggested that the PI3K pathway may be a potential therapeutic target in NSCLC (45) . Here, we extended earlier findings by performing a detailed characterization of candidate biomarkers in the context of the major histologic subtypes of NSCLC, and using preclinical models to determine the association between these biomarkers and selective inhibitors of PI3K signaling. Our findings are consistent with those of previous studies showing that the incidence of PIK3CA mutations in NSCLC is relatively low (1) and they tend to occur in squamous tumors. Our data suggest that the pathway does undergo frequent pathologic activation through alternate mechanisms. In particular, whereas the PIK3CA and 
AKT2 loci were amplified specifically in squamous cell carcinomas, reduced PTEN expression was common in both histologic subtypes, though total PTEN loss was most frequent in squamous cell tumors. In addition to the known association of KRAS and EGFR alterations with adenocarcinoma (38), we also observed frequent loss of LKB1 in adenocarcinoma. The PI3K pathway thus seems to be important in both histologic subtypes of NSCLC, but appears to be activated by distinct molecular aberrations. Biomarker strategies may therefore need to be tailored to histologic disease subtypes to enable optimal patient selection. Our data have implications for diagnostic evaluation during the development of PI3K inhibitors in combination with taxane-containing regimens, as we found that this combination is additive across a range of genetic backgrounds. The implication of this is that the greatest activity may still occur in tumors harboring PI3K and RTK alterations, because these models have the highest intrinsic sensitivity to PI3K inhibition, thus showing the strongest absolute inhibition in combination with chemotherapy.
We initially aimed to analyze cell lines in which key pathway alterations occurred in isolation. However, most of the cell lines showed evidence of more than one molecular alteration in these signaling pathways, highlighting the molecular complexity of lung cancer. RTK activation, PTEN loss, or PIK3CA mutation or amplification were associated with selective PI3K inhibitor sensitivity in the cell line panel. Association of PIK3CA amplification with PI3K inhibitor sensitivity was limited by the relatively small number of cell lines that harbor PIK3CA copy number gains, and it should be noted that other studies have suggested that another gene colocalized under the amplicon, SOX2, is a lineage-specific amplicon and oncogenic driver (46) . However, the observation that PIK3CA amplification is correlated with increased mRNA expression and associated with sensitivity to PI3K inhibition in vitro 
